WallStSmart
XGN

Exagen Inc

NASDAQ: XGN · HEALTHCARE · DIAGNOSTICS & RESEARCH

$3.98
-10.44% today

Updated 2026-06-05

Market cap
$112.83M
P/E ratio
P/S ratio
1.65x
EPS (TTM)
$-0.90
Dividend yield
52W range
$3 – $12
Volume
0.4M

Exagen Inc (XGN) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2012201320142015201720182019202020212022202320242025
Operating cash flow$-7.48M$-6.87M$-10.77M$-11.90M$-10.97M$-9.30M$-9.71M$-14.08M$-20.27M$-32.14M$-14.46M$-13.28M$-13.63M
Capital expenditures$440000.00$172000.00$649000.00$805000.00$567000.00$199000.00$403000.00$455000.00$2.37M$4.32M$828000.00$515000.00$641000.00
Depreciation
Stock-based comp$116000.00$152000.00$279000.00$287000.00$187000.00$114000.00$572000.00$2.69M$4.73M$4.70M$3.62M$1.76M$2.16M
Free cash flow$-7.92M$-7.04M$-11.42M$-12.71M$-11.54M$-9.50M$-10.11M$-14.54M$-22.64M$-36.46M$-15.29M$-13.79M$-14.27M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$0.00$0.00$6.74M$142000.00$390000.00$9.94M
Share repurchases
Debt repayment
Net change in cash$0.00$0.00$0.00$0.00$41.99M

Frequently asked questions

What is Exagen Inc's revenue?

Exagen Inc's trailing twelve-month revenue is $68.38M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is XGN?

In its most recent fiscal year, XGN ran a gross margin of 58.28%, an operating margin of -21.13%, and a net margin of -29.97%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does XGN generate?

XGN produced $-14.27M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is XGN's balance sheet healthy?

XGN holds $32.22M in cash and equivalents against $22.26M in long-term debt, on $17.45M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.